

# Giorgia Marisi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9101850/giorgia-marisi-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

45  
papers

1,014  
citations

19  
h-index

31  
g-index

50  
ext. papers

1,250  
ext. citations

4.6  
avg, IF

4.06  
L-index

#	Paper	IF	Citations
45	Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 745701	5.6	0
44	Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV. <i>OncoTargets and Therapy</i> , <b>2021</b> , 14, 4305-4308	4.4	
43	Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis. <i>Cancers</i> , <b>2021</b> , 13,	6.6	2
42	Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	1
41	Association of and Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 4485-4493	12.9	9
40	The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib. <i>PLoS ONE</i> , <b>2020</b> , 15, e0232449	3.7	23
39	H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages. <i>Cancers</i> , <b>2020</b> , 12,	6.6	19
38	Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma: Preliminary Toxicity and Activity Data in Dogs. <i>Cancers</i> , <b>2020</b> , 12,	6.6	5
37	Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma. <i>Targeted Oncology</i> , <b>2020</b> , 15, 773-785	5	8
36	Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience. <i>Gastrointestinal Tumors</i> , <b>2019</b> , 6, 92-107	1.3	19
35	Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , <b>2019</b> , 8,	5.1	33
34	Immune inflammation indicators in anal cancer patients treated with concurrent chemoradiation: training and validation cohort with online calculator (ARC: Anal Cancer Response Classifier). <i>Cancer Management and Research</i> , <b>2019</b> , 11, 3631-3642	3.6	15
33	Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study. <i>Cancer Management and Research</i> , <b>2019</b> , 11, 1277-1288	3.6	10
32	Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials. <i>OncoTargets and Therapy</i> , <b>2019</b> , 12, 2981-2988	4.4	19
31	Role of SIRT-3, p-mTOR and HIF-1 $\alpha$ in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	16
30	and Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib. <i>Cancers</i> , <b>2019</b> , 11,	6.6	19
29	Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort. <i>Gastrointestinal Tumors</i> , <b>2019</b> , 6, 71-80	1.3	4

28	Impact of physician experience and multidisciplinary team on clinical outcome in patients receiving sorafenib. <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2019</b> , 43, e76-e78	2.4	4
27	Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 681-688	3.3	36
26	Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	44
25	Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?. <i>World Journal of Gastroenterology</i> , <b>2018</b> , 24, 4152-4163	5.6	95
24	Aberrant Metabolism in Hepatocellular Carcinoma Provides Diagnostic and Therapeutic Opportunities. <i>Oxidative Medicine and Cellular Longevity</i> , <b>2018</b> , 2018, 7512159	6.7	65
23	IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab. <i>Cancer Management and Research</i> , <b>2018</b> , 10, 5659-5666	3.6	6
22	Heterogeneity in Colorectal Cancer: A Challenge for Personalized Medicine?. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	80
21	Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival. <i>Oncotargets and Therapy</i> , <b>2018</b> , 11, 6555-6567	4.4	20
20	Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol. <i>Tumori</i> , <b>2018</b> , 104, 476-479	1.7	12
19	Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study. <i>Scientific Reports</i> , <b>2017</b> , 7, 42499	4.9	25
18	Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab. <i>Scientific Reports</i> , <b>2017</b> , 7, 1293	4.9	17
17	Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale. <i>European Journal of Cancer</i> , <b>2017</b> , 86, 106-114	7.5	54
16	Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma. <i>Targeted Oncology</i> , <b>2017</b> , 12, 795-803	5	20
15	Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	31
14	Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review. <i>Oncotarget</i> , <b>2017</b> , 8, 66699-66708	3.3	11
13	Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report. <i>BMC Cancer</i> , <b>2016</b> , 16, 118	4.8	6
12	Prognostic and predictive role of circulating eNOS and EPHB4 in metastatic colorectal cancer patients receiving bevacizumab.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, e23083-e23083	2.2	1
11	Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. <i>Oncotarget</i> , <b>2016</b> , 7, 67142-67149	3.3	76

10	Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial. <i>Oncotarget</i> , <b>2016</b> , 7, 10193-202	3.3	14
9	Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group. <i>Oncotarget</i> , <b>2016</b> , 7, 15243-51	3.3	25
8	eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study. <i>Oncotarget</i> , <b>2016</b> , 7, 27988-99	3.3	26
7	Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. <i>Oncotarget</i> , <b>2016</b> , 7, 46678-46691	3.3	30
6	Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report. <i>BMC Cancer</i> , <b>2016</b> , 16, 429	4.8	25
5	Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 2719-25	4	51
4	eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial. <i>Journal of Translational Medicine</i> , <b>2015</b> , 13, 258	8.5	23
3	Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colon rectal cancer: Results from the ITACa trial.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 617-617	2.2	1
2	Effect of metformin on clinical outcome in advanced HCC patients receiving sorafenib.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e15156-e15156	2.2	
1	Discrepancies between VEGF -1154 G>A polymorphism analysis performed in peripheral blood samples and FFPE tissue. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 13333-43	6.3	10